These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 15775990)

  • 1. Report from Durham.
    Moul J
    Prostate Cancer Prostatic Dis; 2005; 8(1):1. PubMed ID: 15775990
    [No Abstract]   [Full Text] [Related]  

  • 2. Prostate-specific antigen testing. An essential guide to its use and meaning.
    Marks SH
    Adv Nurse Pract; 2001 Apr; 9(4):38-9, 43-4. PubMed ID: 12420434
    [No Abstract]   [Full Text] [Related]  

  • 3. The role of hormonal therapy in prostate brachytherapy. Counterpoint.
    Merrick GS
    Brachytherapy; 2003; 2(1):2-4. PubMed ID: 15062157
    [No Abstract]   [Full Text] [Related]  

  • 4. The role of hormonal therapy in prostate brachytherapy. Point.
    Stock RG
    Brachytherapy; 2003; 2(1):1-2. PubMed ID: 15062156
    [No Abstract]   [Full Text] [Related]  

  • 5. [Prostate specific antigen: utilization modalities and interpretation].
    Hannoun-Levi JM; Ginot A; Thariat J
    Cancer Radiother; 2008 Dec; 12(8):848-55. PubMed ID: 18539498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical approach to the prostate: an update.
    Kutikov A; Guzzo TJ; Malkowicz SB
    Radiol Clin North Am; 2006 Sep; 44(5):649-63, vii. PubMed ID: 17030218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of prostatic carcinoma--controversies].
    Peeling WS
    Pol Tyg Lek; 1996 Feb; 51(6-9):116-20. PubMed ID: 8756751
    [No Abstract]   [Full Text] [Related]  

  • 8. Third international conference on innovations and challenges in prostate cancer: prevention, detection and treatment.
    Carroll PR; Benaron DA; Blackledge G; Coakley FV; D'Amico AV; Higano CS; Iversen P; Kattan M; Nanus DM; Nelson JB; Oh WK; Roach M; Sellers WR; Smith MR; McMann MC; Kantoff PW
    J Urol; 2003 Dec; 170(6 Pt 2):S3-5. PubMed ID: 14610403
    [No Abstract]   [Full Text] [Related]  

  • 9. Prostate specific antigen (PSA) may be a poor marker for progression of prostate cancer after treatment with a combination of chemo-hormonal therapies.
    Sartor O
    J La State Med Soc; 2008; 160(2):99-100. PubMed ID: 18681353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [And what is in the works now? Recent developments in therapy of prostate cancer (interview by Constanze Loffler)].
    Miller K
    MMW Fortschr Med; 2009 Jul; 151(30-33):72-3. PubMed ID: 19722471
    [No Abstract]   [Full Text] [Related]  

  • 11. Systemic therapy for prostate cancer.
    Berry WR
    N C Med J; 2006; 67(2):154-7. PubMed ID: 16752722
    [No Abstract]   [Full Text] [Related]  

  • 12. Can PSA velocity serve as a surrogate endpoint in trials of hormone-refractory, metastatic prostate cancer?
    Ward JF
    Nat Clin Pract Urol; 2006 Jun; 3(6):310-1. PubMed ID: 16763642
    [No Abstract]   [Full Text] [Related]  

  • 13. Prostate health. Early detection, informed choices.
    Mayo Clin Health Lett; 2005 Jun; Suppl():1-8. PubMed ID: 16144084
    [No Abstract]   [Full Text] [Related]  

  • 14. [Prostatic cancer--can unnecessary therapy be avoided? Prostate-specific antigens (PSA) kinetics can guide the management].
    Malmström PU
    Lakartidningen; 2006 Feb 1-7; 103(5):279. PubMed ID: 16512565
    [No Abstract]   [Full Text] [Related]  

  • 15. Prostate Cancer and Prostatic Diseases. Editor's comments.
    Freedland SJ
    Prostate Cancer Prostatic Dis; 2010 Dec; 13(4):295. PubMed ID: 21068743
    [No Abstract]   [Full Text] [Related]  

  • 16. [Cooperative care between urologists and general practitioners].
    Fukagai T; Morita M; Yoshida H
    Nihon Rinsho; 2002 Dec; 60 Suppl 11():459-64. PubMed ID: 12599619
    [No Abstract]   [Full Text] [Related]  

  • 17. Prostatic problems in the aged.
    Pincus MB
    Mt Sinai J Med; 1980; 47(2):205-7. PubMed ID: 6156408
    [No Abstract]   [Full Text] [Related]  

  • 18. Controversy over prostate-specific antigen screening has shifted from mortality to overtreatment issues.
    Ito K
    Int J Urol; 2009 Sep; 16(9):711-12. PubMed ID: 19777638
    [No Abstract]   [Full Text] [Related]  

  • 19. How early is early: androgen deprivation for prostate-specific antigen relapse in prostate cancer.
    Duchesne GM; Syme R; Howell D
    J Clin Oncol; 2006 Jun; 24(18):2964; author reply 2965. PubMed ID: 16782936
    [No Abstract]   [Full Text] [Related]  

  • 20. High-grade prostatic intraepithelial neoplasialike ductal adenocarcinoma of the prostate: a clinicopathologic study of 28 cases.
    Tavora F; Epstein JI
    Am J Surg Pathol; 2008 Jul; 32(7):1060-7. PubMed ID: 18496142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.